TRIUMEQ QD vs continuing ARV regimen (N=551)ĭTG 50mg BD + OBR** (N=183)-single-arm studyįDCs have greatly simplified the treatment of patients with HIVĭTG is a booster-free INI approved for treatment of HIV-1 infection in combinationĪBC and 3TC are NRTIs available as a single pill (Kivexa) Presented at 21st International AIDS Conference, 18th-22nd July, 2016 Durban, South Africa. Presented at 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17th-21st September,Ģ015 San Diego, CA. Presented at 21st International AIDS Conference, 18th-22nd July, 2016 Durban, South Africa.Ībstract THAB0205LB. TRIUMEQ Summary of Product Characteristics, January 2017 Weller S et al. Separate co-administered tablet formulations of DTG + ABC/3TC In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/3TC 300 mg were usedīioequivalence was demonstrated between the TRIUMEQ as a single-pill and the *In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/3TC 300 mg were used.ĭTG, dolutegravir ABC, abacavir 3TC, lamivudine Prescribing information is available at the end of this presentation
0 Comments
Leave a Reply. |